Cue Biopharma, Inc. (CUE) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Piper Sandler Reiterates Overweight Rating on Cue Biopharma (CUE)
August 20, 2024 5:16 AM EDTPiper Sandler analyst Ed Tenthoff reiterated an Overweight rating and $3.00 price target on Cue Biopharma (NASDAQ: CUE).
The analyst comments "Cue and partner Ono anticipate selecting a development candidate for CUE-401 for autoimmune and inflammatory diseases in 1H:25, on which... More
